Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Drug: Ivonescimab for PD-L1 Positive NSCLC
Randomised, double-blind, phase 3 trial [HARMONi-2] PD-L1-positive advanced non-small cell lung cancer Ivonescimab 20 mg/kg IV Q3W vs Pembrolizumab 200 mg IV Q3W
New Protocol: Pembrolizumab and Bevacizumab for Nasopharyngeal Cancer
Randomised, open-label, phase 2 trial Platinum-resistant recurrent or metastatic nasopharyngeal carcinoma Pembrolizumab (200 mg IV q21d) vs. Pembrolizumab (200 mg IV q21d) + Bevac
New Reference: Lenvatinib and Pembrolizumab for HCC
Multicenter, randomised, double-blind, phase 3 study (LEAP-012) Unresectable, non-metastatic hepatocellular carcinoma TACE + lenvatinib + pembrolizumab (n=237) vs TACE + placebo (n
New Protocol: Osimertinib with Ramucirumab for EGFR-Mutated NSCLC
Randomized, open-label, multicenter, phase 2 study [RAMOSE trial] First-line metastatic EGFR-mutant NSCLC Osimertinib + Ramucirumab (n = 93) vs. Osimertinib alone (n = 46) unti
New Indication: Ibrutinib with Venetoclax for Mantle Cell Lymphoma
Randomised, double-blind, placebo-controlled phase 3 trial (SYMPATICO) Relapsed or refractory mantle cell lymphoma (MCL) after 1-5 prior therapies Ibrutinib 560 mg daily + Venetocl
New Indication: Enfortumab Vedotin for Head and Neck Cancer
Open-label, multicohort, phase II study (EV-202) Recurrent/metastatic head and neck cancer previously treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitors Enfortumab
New Protocol: Acalabrutinib + Venetoclax for Fixed Duration with/without Obinutuzumab
Phase 3, multicenter, open-label, randomized trial (AMPLIFY) Previously untreated CLL without del(17p) or TP53 mutation Acalabrutinib–venetoclax vs. acalabrutinib–venetoclax–
New Reference: Zenocutuzumab for NRG1 Fusion-Positive Cancer
Phase 2, open-label, multicenter clinical trial (eNRGy) Advanced/metastatic solid tumors with NRG1 fusion Zenocutuzumab 750 mg IV every 2 weeks
New Protocol: Ipilimumab + Nivolumab for MSI-H Colorectal Cancer
Phase 3, multicenter, open-label, randomized clinical trial (CheckMate 8HW) Unresectable or metastatic colorectal cancer with MSI-H/dMMR status, across all treatment lines Nivoluma
